U.S. Food et al., 2004-05-19: The FDA application record for NDA 020449 shows Sanofi Aventis US as holder and an action dated 19 May 2004 on supplement 28, an efficacy supplement adding a new indication – the prostate cancer indication based on TAX 327.
Efficacy-New Indication
HTML record, unpaginated
U.S. Food et al., 2004-05-19: The FDA application record for NDA 020449 shows Sanofi Aventis US as holder and an action dated 19 May 2004 on supplement 28, an efficacy supplement adding a new indication – the prostate cancer indication based on TAX 327. Funder: n/a (regulatory record). Maker: Sanofi Aventis US (Taxotere). Comparator: n/a. The 2004 approval label attached to SUPPL-28 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020449s028lbl.pdf) carries the new indication at page 17: 'Prostate Cancer: TAXOTERE in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.' A later supplement, SUPPL-29 (08/18/2004), added the adjuvant breast cancer indication, not a prostate one. Study type: regulatory record.
